Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | See Remarks | September 08, 2020 | September 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date September 08, 2020 · Filed September 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,000 |
Reported balance
After 2020-09-08 transaction · row 1
1 source rowRow 1 · 2020-09-08 · Grant · Acquired 35,000 · Balance 35,000 F1: Shares acquired are shares of restricted stock awarded effective on September 8, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest in full on July 1, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.58 · Expires 2030-09-08 | Direct | 80,000 |
Reported balance
After 2020-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-08 · Grant · Acquired 80,000 · Balance 80,000 F2: These shares shall vest in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded effective on September 8, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest in full on July 1, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.
F2: These shares shall vest in full on the one year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2020 Filed Sep 10, 2020 20:07 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $12.58 | $0.00 |
DisclosureSEC source: 0001104659-20-103943 · tm2030582d1_4.xml · derivative · entry 2 Waclawski Anthony · CIK 0001823486 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-09-08 F2 · derivative.exercise_date: These shares shall vest in full on the one year anniversary of the date of grant. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:07 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-103943 · tm2030582d1_4.xml · nonDerivative · entry 1 Waclawski Anthony · CIK 0001823486 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Shares acquired are shares of restricted stock awarded effective on September 8, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest in full on July 1, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.